Heartseed Inc.


Development of a treatment method that creates heart cells from iPS cells and transplants them into heart tissue

Heartseed has many unique technologies necessary to spread myocardial regenerative medicine, such as the technology to create high-purity cardiomyocytes from iPS cells and the technology to transplant the created cardiomyocytes. We have received the “Minister of Science and Technology Policy Award” at the Japan Venture Awards 2021 and the “Minister of Education, Culture, Sports, Science, and Technology Award” at the University Venture Awards 2021. We also have a track record of alliances with major overseas pharmaceutical companies.

Establishment Date
November 2015
Myocardial regenerative medicine using iPS cells
Keiichi Fukuda, Representative Director of the Board and CEO

KII’s Perspective

We hope that myocardial regenerative medicine will become commonplace as a new method of treating heart failure.

KII growth support

Dispatch of board observers